Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.45 |
| ▸ | ATXN2 | Q99700 | 5/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22607225 | 1.00 | ENPP2 (0.45) | ENPP2ATXN2DGAT2EPHX2NTRK1 | |
| SCHEMBL21323015 | 1.00 | ENPP2 (0.45) | ENPP2ATXN2DGAT2EPHX2NTRK1 | |
| SCHEMBL16963195 | 1.00 | ENPP2 (0.45) | ENPP2ATXN2DGAT2EPHX2NTRK1 | |
| SCHEMBL21323110 | 0.94 | ENPP2 (0.46) | ENPP2ATXN2DGAT2NTRK1KCNH2 | |
| SCHEMBL16962785 | 0.94 | ENPP2 (0.46) | ENPP2ATXN2DGAT2NTRK1KCNH2 | |
| SCHEMBL16962814 | 0.91 | ATXN2 (0.39) | ENPP2ATXN2DGAT2NTRK1KCNH2 | |
| SCHEMBL21322858 | 0.91 | ATXN2 (0.39) | ENPP2ATXN2DGAT2NTRK1KCNH2 | |
| SCHEMBL21323370 | 0.91 | ATM (0.42) | ENPP2ATXN2 | |
| SCHEMBL16962815 | 0.91 | ATM (0.42) | ENPP2ATXN2 | |
| SCHEMBL17310878 | 0.87 | ENPP2 (0.55) | ENPP2ATXN2DGAT2KCNH2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |